R&D Price Inflation, Real BERD and Innovation: Pharmaceuticals, OECD 1980-2000
Messinis, George (2004) R&D Price Inflation, Real BERD and Innovation: Pharmaceuticals, OECD 1980-2000. Working Paper. Victoria University, Melbourne, Australia.Full text for this resource is not available from the Research Repository.
Research in pharmaceuticals suggests there is a growing imbalance in the spatial distribution of business expenditure in R&D (BERD) and R&D productivity has declined. This evidence derives from data using GDP price deflators to adjust for price inflation but Dougherty et al. (2003) show them to be inappropriate. This paper draws on economic theory and panel estimation techniques to develop Griliches-Jaffe-type R&D price deflators for the pharmaceutical industry in the OECD. The paper also re-examines the hypotheses that Europe is an innovation laggard and that R&D productivity has declined. The evidence shows Europe is not a laggard in real BERD, R&D productivity has improved throughout the OECD except Japan, and the USA has consolidated its leadership in patents and R&D productivity.
|Item Type:||Monograph (Working Paper)|
|Uncontrolled Keywords:||price inflation; pharmaceuticals; productivity; pharmaceutical industry; R&D expenditures; drugs; inflation; innovation; patents|
|Subjects:||RFCD Classification > 320000 Medical and Health Sciences
Faculty/School/Research Centre/Department > Centre for Strategic Economic Studies (CSES)
|Depositing User:||Mr Angeera Sidaya|
|Date Deposited:||21 Oct 2005|
|Last Modified:||16 May 2012 23:59|
|ePrint Statistics:||View download statistics for this item|
Repository staff only